Articles
🇪🇺 EuropeExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and EMA regulations.
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Era
Purdue Pharma, the manufacturer of OxyContin, is ceasing operations as part of a $7.4 billion settlement to address its role in the opioid crisis. This landmark agreement aims to resolve thousands of lawsuits and redirect company assets towards addiction treatment and prevention.
Orchard Therapeutics OTL-201: Innovation Passport for MPS-IIIA
Orchard Therapeutics has secured an Innovation Passport designation from the MHRA for its investigational gene therapy, OTL-201, targeting MPS-IIIA. This marks a significant step in accelerating development and access for patients with Sanfilippo syndrome type A.
NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs
This article examines the role of NICE Technology Appraisals in shaping market access strategies for innovative oncology drugs, including Pembrolizumab.
MHRA Post-Brexit Drug Approval: What You Need to Know
Learn about the MHRA's new drug approval process post-Brexit and its impact on the availability of essential medications like Ozempic for diabetes.
CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights
Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.
Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation
This article examines how biosimilar adoption in the EU is reshaping the market landscape for biologics like Adalimumab after patent expirations and under HTA regulations.
EMA Conditional Marketing Authorizations: Evolving Framework & PRAC Safety Insights
This article delves into the evolving framework of EMA Conditional Marketing Authorizations and highlights PRAC's safety insights for drug XYZ in cancer therapy.
MHRA Drug Approval Divergence: UK vs EU Market Access & Investment Impact
This article delves into the differences in MHRA drug approval processes for [Drug Name] in [Indication], highlighting their effects on market access and investment strategies in the UK and EU.
MHRA Divergence from EMA: What You Need to Know for EU Market Access
This article explores the key differences between MHRA and EMA regulations, focusing on how they affect market access for drugs like XYZ in the EU.
Auvelity FDA Approval: A New MDD Treatment Option
The FDA has approved Auvelity, a novel oral therapy from Axsome Therapeutics, for the treatment of major depressive disorder (MDD). This marks a significant advancement in MDD treatment options.
EU Pharmaceutical Legislation Reform: Impact on Orphan Drug Market Exclusivity
This article examines how recent EU pharmaceutical legislation reforms could reshape market exclusivity for orphan drugs, affecting access to treatments for rare diseases.
Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.
EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU
Linvoseltamab has received EMA's Conditional Marketing Authorization for treating relapsed/refractory multiple myeloma, offering new hope for patients in the EU.
EU Clinical Trials Regulation Impact on Rare Disease Drug Development
This article examines the impact of the EU Clinical Trials Regulation on the development of drugs for rare diseases, focusing on challenges and opportunities for treatments.
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
The upcoming EU pharmaceutical legislation reform will significantly affect generics and biosimilars, shaping the future of drug access and innovation in 2026-27.
Bispecific Antibody Approvals in EU: Teclistamab & Elranatamab Review
This article reviews the recent EU approvals of teclistamab and elranatamab, highlighting their significance in treating multiple myeloma.
EMA Conditional Approvals CAR-T: Insights on Relapsed B-Cell Lymphomas
This article delves into the insights and implications of EMA's conditional approvals for CAR-T therapies in the management of relapsed B-cell lymphomas.
EMA Conditional Approval Pathway: Insights from Repotrectinib Oncology Approval
This article delves into the EMA Conditional Approval Pathway, highlighting key insights from the oncology approval of Repotrectinib for advanced cancer treatment.
EMA Conditional Marketing Authorization: Oncology Approvals & EU Patient Access
This article delves into the EMA's Conditional Marketing Authorization process, focusing on oncology drug approvals and their impact on patient access in the EU.
EMA Accelerated Assessment Biologics: Market Uptake Forecast in EU
This article analyzes the EMA's accelerated assessment process for biologics, focusing on XYZ Drug for cancer and its projected market uptake in the EU.